company

Intra-Cellular Therapies, Inc.

Intra-Cellular
CIK 0001567514
as of 2026-07-01
Monitor thisAsk about this
at a glance
Cash $306.9M (as of 2024-12-31)
Revenue $199.2M
12 trials sponsored · 10 assets in the graph
Synthesized from structured facts only — each point cited above.

Financials

SEC EDGAR XBRL · latest period per metric
Cash$306.9M2024-12-31
Ga Expense$504.5M2024-12-31
Net Income Loss-$16.9M2024-12-31
Revenue$199.2M2024-12-31
Rnd Expense$236.1M2024-12-31
Stockholders Equity$1.1B2024-12-31
Total Assets$1.4B2024-12-31

Pipeline

10 assets
Lumateperone (Caplyta)RisperidoneITI-214 Dose AITI-214 Dose BITI-214 Dose CITI-214 Dose D (Elderly)ITI-214 Dose EITI-214 Dose FITI-214 Dose GITI-214 Dose H

Recent filings

SEC EDGAR
SCHEDULE 13G/Aopen ↗2025-06-05
15-12Gopen ↗2025-04-14
EFFECTopen ↗2025-04-09
4open ↗2025-04-02
4open ↗2025-04-02
4open ↗2025-04-02
4open ↗2025-04-02
4open ↗2025-04-02
POS AMopen ↗2025-04-02
4open ↗2025-04-02
S-8 POSopen ↗2025-04-02
POSASRopen ↗2025-04-02

Facts & assertions

10 sourced
Financial Status
pre-revenue / loss-making
Implied Monthly Burn
5,640,703
Implied Runway Months
54.4
Latest Cash
306,948,000
Latest Ga Expense
52,473,573
Latest Net Income Loss
-16,885,000
Latest Revenue
199,223,000
Latest Rnd Expense
66,819,000
Latest Stockholders Equity
1,148,460,000
Latest Total Assets
1,366,912,000
relationships
The graph out of here
asset
Lumateperone (Caplyta)
small molecule
drug
Risperidone
small molecule
drug
ITI-214 Dose A
small molecule
drug
ITI-214 Dose B
small molecule
drug
ITI-214 Dose C
small molecule
drug
ITI-214 Dose D (Elderly)
small molecule
drug
ITI-214 Dose E
small molecule
drug
ITI-214 Dose F
small molecule
drug